Umbilicus Bupivacaine

PreclinicalSmall molecule

SSeoul National University Hospital

Umbilicus Bupivacaine is one of 7 small molecule programs targeting Spinal Anesthesia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Spinal AnesthesiaUnknown status

Spinal AnesthesiaPreclinical

Unknown status

Competition

Competitive Landscape

10 competitors in Spinal Anesthesia

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Approved

7 2

Catapres

Boehringer Ingelheim

Approved

4 3

Chirocaine

PPurdue Pharma LP

Approved

4 4

Anerem

AAcacia Pharma Ltd

Approved

1 5

Ephedrine Sulfate

DDr. Reddys Laboratories, SA

Preclinical

4 6

Dexmedetomidine 5 Micrograms

UUdayana University

Preclinical

1 7

Umbilicus Bupivacaine

SSeoul National University Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Spinal Anesthesia1 trial

Effect of the Height of the Operating Table During Spinal Anesthesia

Unknown status·SSeoul National University Hospital·N/A·NCT02373410·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Umbilicus Bupivacaine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Umbilicus Bupivacaine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Umbilicus Bupivacaine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Seoul National University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSeoul National University Hospital

Umbilicus Bupivacaine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Spinal Anesthesia1 trial

References

Drug Info

Quick Facts

Related News